Navigation Links
Apexigen, Inc. Announces Collaboration for Antibody Discovery
Date:12/7/2010

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs.  Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.  While financial details were not disclosed, Apexigen will receive an upfront license fee, and is eligible to receive future milestone and royalty payments if certain development and commercialization milestones are achieved.

Apexigen's antibody technologies produce a broad diversity of antibodies with high specificity, high affinity, and unique epitopes, and can successfully generate antibodies against challenging antigens where competing technologies fail. This enables the development of 'best-in-class' therapeutic antibodies.  

"We're excited about this collaboration and look forward to working closely with Centocor R&D," said Dr. Xiaodong Yang, President & CEO of Apexigen.  "Our goal is to become a world leader in the development of best-in-class therapeutic antibodies.  To achieve this goal, we plan to collaborate with partners while also developing our own product pipeline."

About Apexigen

Apexigen, Inc. is a biopharmaceutical company focused on the discovery and development of best-in-class therapeutic antibodies.  Apexigen has exclusive rights to the proprietary antibody technologies that were developed by Epitomics, Inc. for the development and commercialization of human therapeutics. In addition, Apexigen assumed development and commercialization responsibility for a pipeline of therapeutic product programs initiated by Epitomics.

Located in Burlingame, CA, Apexigen is actively developing its internal therapeutic product pipeline and seeking to form collaborative relationships with pharmaceutical and biotechnology companies for the discovery and development of pharmaceutical products based on its humanized rabbit monoclonal antibody technologies.  More information about Apexigen is available at www.apexigen.com.Contact Mark Nevins, Vice President, Business DevelopmentTel: 650-931-6236, ext. 502Email:  mnevins@apexigen.com
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
2. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
3. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
4. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
5. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
6. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
9. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
10. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
11. Curemark Announces Four New Sites Participating in Autism Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  Astellas Pharma Inc. (TSE: 4503, ... today that it has successfully completed, through its indirect ... to purchase all issued and outstanding shares of common ... CEO: Paul Wotton , "Ocata") for a price ... cash ("Tender Offer"). Astellas commenced the Tender Offer on ...
(Date:2/10/2016)... , Feb. 10, 2016  The ... Nursing received an in-kind gift from ... a VeinViewer® Vision vein finder for the ... help students as they learn how to ... technology with traditional technique. ...
(Date:2/10/2016)... , Feb. 10, 2016 ... synergistic confluence of various technologies that results ... previously unavailable. These opportunities create a cyclical ... in turn, drives the development of new ... is characterized by technology convergences, which are ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... 10 Best Water is excited to announce ... brand owners that topped the list as a result of their commitment to offering ... brand was Tibet 5100, a top notch water company that specializes in providing the ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & ... PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless steel with ... of biological samples while operating at ultra-high pressures of 20,000 psi. The higher ...
(Date:2/10/2016)... Washington, DC (PRWEB) , ... February 10, 2016 , ... ... highest level since the start of Medicare Part D a decade ago, according to ... collecting comments from older adults on how they are coping with rapidly rising costs. ...
Breaking Medicine News(10 mins):